Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

NCT06271057 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT06271057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06271057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 2
Overall status
Recruiting
Start date
June 14, 2024
Completion date
December 31, 2028
Enrollment
65 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma refractory, refractory high grade b-cell lymphoma, refractory primary mediastinal large b-cell lymphoma, refractory transformed b-cell non-hodgkin lymphoma